153 related articles for article (PubMed ID: 27910071)
1. PI3K/PTEN/AKT Genetic Mouse Models of Endometrial Carcinoma.
Joshi A; Ellenson LH
Adv Exp Med Biol; 2017; 943():261-273. PubMed ID: 27910071
[TBL] [Abstract][Full Text] [Related]
2. [Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].
Yang X; Dong Y; Zhang XM; Liang Y; Zhang Y; Meng YT; Wang Y; Wang W; Nong L; Li T; Liao QP
Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):799-804. PubMed ID: 22336203
[TBL] [Abstract][Full Text] [Related]
3. Activated mutant p110α causes endometrial carcinoma in the setting of biallelic Pten deletion.
Joshi A; Miller C; Baker SJ; Ellenson LH
Am J Pathol; 2015 Apr; 185(4):1104-13. PubMed ID: 25698082
[TBL] [Abstract][Full Text] [Related]
4. Correlation between PTEN expression and PI3K/Akt signal pathway in endometrial carcinoma.
Gao Q; Ye F; Xia X; Xing H; Lu Y; Zhou J; Ma D
J Huazhong Univ Sci Technolog Med Sci; 2009 Feb; 29(1):59-63. PubMed ID: 19224164
[TBL] [Abstract][Full Text] [Related]
5. JQ1 suppresses tumor growth via PTEN/PI3K/AKT pathway in endometrial cancer.
Qiu H; Li J; Clark LH; Jackson AL; Zhang L; Guo H; Kilgore JE; Gehrig PA; Zhou C; Bae-Jump VL
Oncotarget; 2016 Oct; 7(41):66809-66821. PubMed ID: 27572308
[TBL] [Abstract][Full Text] [Related]
6. Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.
Bradford LS; Rauh-Hain A; Clark RM; Groeneweg JW; Zhang L; Borger D; Zukerberg LR; Growdon WB; Foster R; Rueda BR
Gynecol Oncol; 2014 May; 133(2):346-52. PubMed ID: 24561032
[TBL] [Abstract][Full Text] [Related]
7. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.
Cheung LW; Hennessy BT; Li J; Yu S; Myers AP; Djordjevic B; Lu Y; Stemke-Hale K; Dyer MD; Zhang F; Ju Z; Cantley LC; Scherer SE; Liang H; Lu KH; Broaddus RR; Mills GB
Cancer Discov; 2011 Jul; 1(2):170-85. PubMed ID: 21984976
[TBL] [Abstract][Full Text] [Related]
8. Gankyrin plays an essential role in estrogen-driven and GPR30-mediated endometrial carcinoma cell proliferation via the PTEN/PI3K/AKT signaling pathway.
Zhang J; Yang Y; Zhang Z; He Y; Liu Z; Yu Y; Wu S; Cai B; Feng Y
Cancer Lett; 2013 Oct; 339(2):279-87. PubMed ID: 23142288
[TBL] [Abstract][Full Text] [Related]
9. Long Noncoding RNA HOTAIR Promotes Endometrial Carcinoma Cell Proliferation by Binding to PTEN via the Activating Phosphatidylinositol 3-Kinase/Akt Signaling Pathway.
Zhang XH; Hu P; Xie YQ; Kang YJ; Li M
Mol Cell Biol; 2019 Dec; 39(23):. PubMed ID: 31527078
[TBL] [Abstract][Full Text] [Related]
10. PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations.
Velasco A; Bussaglia E; Pallares J; Dolcet X; Llobet D; Encinas M; Llecha N; Palacios J; Prat J; Matias-Guiu X
Hum Pathol; 2006 Nov; 37(11):1465-72. PubMed ID: 16949921
[TBL] [Abstract][Full Text] [Related]
11. Mutual contribution of Pten and estrogen to endometrial carcinogenesis in a PtenloxP/loxP mouse model.
Saito F; Tashiro H; To Y; Ohtake H; Ohba T; Suzuki A; Katabuchi H
Int J Gynecol Cancer; 2011 Nov; 21(8):1343-9. PubMed ID: 21989218
[TBL] [Abstract][Full Text] [Related]
12. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
[TBL] [Abstract][Full Text] [Related]
13. Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma.
Kanamori Y; Kigawa J; Itamochi H; Shimada M; Takahashi M; Kamazawa S; Sato S; Akeshima R; Terakawa N
Clin Cancer Res; 2001 Apr; 7(4):892-5. PubMed ID: 11309338
[TBL] [Abstract][Full Text] [Related]
14. PI3K Pathway Effectors pAKT and FOXO1 as Novel Markers of Endometrioid Intraepithelial Neoplasia.
Strickland AL; Rivera G; Lucas E; John G; Cuevas I; Castrillon DH
Int J Gynecol Pathol; 2019 Nov; 38(6):503-513. PubMed ID: 30256235
[TBL] [Abstract][Full Text] [Related]
15. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
[TBL] [Abstract][Full Text] [Related]
16. Akt-mediated phosphorylation and activation of estrogen receptor alpha is required for endometrial neoplastic transformation in Pten+/- mice.
Vilgelm A; Lian Z; Wang H; Beauparlant SL; Klein-Szanto A; Ellenson LH; Di Cristofano A
Cancer Res; 2006 Apr; 66(7):3375-80. PubMed ID: 16585156
[TBL] [Abstract][Full Text] [Related]
17. PI3K/AKT pathway activation in bladder carcinogenesis.
Calderaro J; Rebouissou S; de Koning L; Masmoudi A; Hérault A; Dubois T; Maille P; Soyeux P; Sibony M; de la Taille A; Vordos D; Lebret T; Radvanyi F; Allory Y
Int J Cancer; 2014 Apr; 134(8):1776-84. PubMed ID: 24122582
[TBL] [Abstract][Full Text] [Related]
18. Evidence for different expression profiles for c-Met, EGFR, PTEN and the mTOR pathway in low and high grade endometrial carcinomas in a cohort of consecutive women. Occurrence of PIK3CA and K-Ras mutations and microsatellite instability.
Thoury A; Descatoire V; Kotelevets L; Kannengiesser C; Bertrand G; Theou-Anton N; Frey C; Genestie C; Raymond E; Chastre E; Lehy T; Walker F
Histol Histopathol; 2014 Nov; 29(11):1455-66. PubMed ID: 24811063
[TBL] [Abstract][Full Text] [Related]
19. Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma.
Ollikainen M; Gylling A; Puputti M; Nupponen NN; Abdel-Rahman WM; Butzow R; Peltomäki P
Int J Cancer; 2007 Aug; 121(4):915-20. PubMed ID: 17471559
[TBL] [Abstract][Full Text] [Related]
20. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
Ogawa K; Sun C; Horii A
Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
